New Findings on the Treatment of Renal Cell Carcinoma: Highlights from ASCO 2023

home / readout-360 / new-findings-on-the-treatment-of-renal-cell-carcinoma-highlights-from-asco-2023

Expert GU oncologists discuss recent data updates in the treatment of renal cell carcinoma from the ASCO 2023 Annual Meeting.

EP. 1: Lenvatinib Plus Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma (aRCC)

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 12th 2023

Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.

EP. 2: Pembrolizumab Plus Axitinib Versus Sunitinib for First-Line Treatment of Advanced Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 12th 2023

Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.

EP. 3: Comparing IO/TKI and IO/IO First-Line Treatment Regimens in Advanced RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 19th 2023

Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.

EP. 4: Selecting an Appropriate Frontline Treatment Regimen for Patients With Advanced RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 19th 2023

Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.

EP. 5: Treating Patients With Metastasized RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 28th 2023

Experts discuss the optimal treatment of patients with renal cell carcinoma and brain, bone, or lung metastases.

EP. 6: Managing Adverse Events in Patients With Advanced RCC Receiving an IO/TKI Combination Regimen

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 28th 2023

Dr Moshe Ornstein details the adverse events seen with IO/TKI combination regimens in patients with advanced renal cell carcinoma and the best strategies for management.

EP. 7: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Metastatic RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 2nd 2023

Moshe Ornstein, MD, reviews the design and efficacy and safety data from the phase 3 CONTACT-03 study in metastatic renal cell carcinoma.

EP. 8: Emerging Advancements in the Treatment of Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 2nd 2023

The panel highlights novel agents under investigation for the treatment of clear cell renal cell carcinoma.

EP. 9: Recent Data Updates in the Treatment of Non-Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 9th 2023

Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.